Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Murepavadin - Spexis

Drug Profile

Murepavadin - Spexis

Alternative Names: POL 7080; POL 7080 acetate; RG 7929; RO 7033877

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Polyphor; University of Zurich
  • Developer Polyphor; Spexis
  • Class Antibacterials; Cyclic peptides; Epitopes; Macrocyclic compounds; Peptidomimetics
  • Mechanism of Action Imp protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pseudomonal infections
  • Discontinued Gram-negative infections; Nosocomial infections; Ventilator associated pneumonia

Most Recent Events

  • 30 May 2023 Spexis plans a phase Ib/II trial for Cystic fibrosis and Non-cystic fibrosis bronchiectasis in 2023
  • 10 Jan 2023 Spexis completes a phase I trial for Pseudomonal infections (In volunteers) (Inhalent)
  • 09 Jan 2023 Adverse events and pharmacokinetics data from a phase I trial for Pseudomonal infections (In volunteer) released by Spexis
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top